Additionally, clinical sample studies are needed to validate the expression levels of miR-497-5p and SOX5 in NSCLC patients and their correlation with prognosis, while clinical trials should be initiated to evaluate the safety and efficacy of DHA in NSCLC treatment. This evidence concerns the gene SOX5 and non-small cell lung carcinoma.